[31P-am405] Survey of pharmacists' palliative care interventions for cancer patients in a hospital setting

○Sachiko Arai¹, Ryoko Sasaki¹, Tomoya Komori¹, Tadashi Wakasugi¹, Hirofumi Koike¹, Yukiko Sahashi¹ (1. Pharm. Dept., Yokohama City Univ. Hosp.)

[31P-am406] Survey on the rate of carrying and bringing medication notebooks

○Osamu Kazama¹, Masayo Shiotani², Syun Satou³, Yoshii Hirose³, Yuu Hayasaka⁴, Yurika Minamizawa¹, Shiori Kawamura⁵, Tsuyoshi Koubo⁶, Takuya Shima⁷ (1. Hibari Yakkyoku Mutsuuraten, 2. Hibari Yakkyoku Totsukanishiguchiten, 3. Hibari Yakkyoku Totsukahigashiguchiten, 4. Hibari Yakkyoku Totsukaten, 5. Hibari Yakkyoku Kawasakiten, 6. Hibari Yakkyoku Shinkawabashiten, 7. Hibari Yakkyoku Machidaten)

[31P-am407S] A comprehensive search for adverse events caused by abiraterone and enzalutamide using FDA adverse event reporting system

○Haruka Aizawa¹, Rikuto Masuda¹, Yoshihiro Noguchi¹, Masataka Shishido¹, Yuta Teshigawara¹, Tomoaki Yoshimura¹ (1. Gifu Pharm. Univ.)

[31P-am408S] Risk assessment of cardiovascular adverse events with enzalutamide compared to abiraterone using real-world data.

○Rikuto Masuda¹, Haruka Aizawa¹, Shunsuke Yoshizawa¹, Yoshihiro Noguchi ¹, Yuki Nomura¹, Mitsuru Saguchi¹, Kazuhiro Iguchi¹, Tomoaki Yoshimura¹ (1. Gifu Pharm. Univ.)

[31P-am409S] Effect of Hyperbilirubinemia at the Beginning of Treatment on Myelosuppression in GnP Therapy for Pancreatic Cancer (Report 2)

○Saki Touda¹, Shigekazu Hirai², Tomohiro Ariyama^1,3, Masaki Takigawa¹, Masako Kinoshita¹, Toru Masaka¹, Masayuki Masuda¹ (1. Toho Univ., 2. Pharmaceutical Unit, Sakura Medical Center, Toho University, 3. Department of Pharmacy, Japanese Red Cross Medical Center)

[31P-am410] Outcome analysis of patients treated with gemcitabine and nab-paclitaxel for unresectable pancreatic cancer

○Hiroaki Sato¹, Ryohko Suzuki¹, Daisuke Komazawa², Toshiyasu Iwao² (1. Aizu chuo hospital pharmaceutical department, 2. Aizu chuo hospital department of gastroenterology)

[31P-am411] Characteristics of Immune-Related Adverse Events (irAEs) in Patients with Skin Cancer Treated with Immune Checkpoint Inhibitors: An Attempt to Create a Predictive Model for irAEs

○Sorama Aoki¹, Sae Ishikawa¹, Kenji Hoshi¹, Junko Kawakami¹ (1. Fac. Pharm., Tohoku Med. Pharm. Univ.)

[31P-am412] Study on the influence of body weight on Lenvatinib dosage in Pembrolizumab/Lenvatinib chemotherapy

○Takeyori Morimoto¹, Taisuke Sugino¹, Akiyoshi Inada¹, Naohiro Ohara¹, Toshiyuki Doi¹ (1. Department of Pharmacy, National Hospital Organization Kyoto Medical Center)

[31P-am413S] Analysis of risk factors for cisplatin-induced nausea and vomiting during the extended overall phase in patients receiving cisplatin-based chemotherapy

○Rika Miyauchi¹, Hiroshi Inano², Yoshihito Morimoto¹, Kanata Kitagawa², Akito Shibuya², Kozue Nakagomi², Tomohiro Ota², Yuri Anzo², Aiko Shono¹, Masayoshi Hirohara¹, Katsuya Otori^2,3, Kazuhiro Watanabe¹ (1. Showa. Pharm. Univ., 2. Dept. Pharm., Kitasato. Univ. Hosp., 3. Kitasato Univ. Sch. of Pharm.)

[31P-am414] Timing and clinical course of the onset of nausea and vomiting following Trastuzumab Deruxtecan therapy in breast cancer patients.

○Yusuke Nakatani¹, Toshinori Hirai¹, Kanako Saito², Takuya Iwamoto¹ (1. Dept. Pharm., Mie Univ. Hosp., 2. Dept. Med. Oncol., Mie Univ. Hosp.)

[31P-am415S] The potential of MCT4 and NHE1 inhibitors for PD-L1 protein expression targeting the microenvironment

○Nao Chikata¹, Takanobu Nadai¹, Shuichi Kishimoto¹, Shoji Fukushima¹ (1. Fac. Pharm. Sci., Kobe Gakuin Univ.)

[31P-am416S] Relationship between oral mucositis, salivary inflammatory mediators, and oral moisture in patients with cancer

○Mai Onuki¹, Anna Kiyomi¹, Kensuke Yoshida², Akira Kurokawa³, Kyosuke Yamazaki¹, Naoto Hoshino², Chie Saito², Masayoshi Koga², Hiroko Kanemaru³, Akira Toyama², Munetoshi Sugiura¹ (1. Department of Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, 2. Department of Pharmacy, Niigata University Medical and Dental Hospital, 3. Oral Management Clinic for Medical Cooperation, Niigata University Medical and Dental Hospital)

[31P-am417S] Investigation of drug sensitivity in the Osteoblastic niche of acute myeloid leukemia.

○Sakura Ikeuchi¹, Soichiro Ushio², Yasuhisa Tatebe³, hirohumi hamano^1,3, Yoshito Zamami^1,3 (1. Fac. Pharm. Sci., Okayama Univ.,, 2. Fac. Pharm. Sci., Fukuoka Univ.,, 3. Dept. Pharm., Okayama Univ. Hosp)

[31P-am418] Comparison of side effects of bevacizumab predecessor and biosimilar in patients with unresectable advanced/recurrent colorectal cancer

○Yasuyuki Suzuki¹, Yusei Fujisawa¹ (1. Akita Kousei Medical Center)

[31P-am419S] Subjective symptoms and adverse events of immune checkpoint inhibitor therapies using medical records and patient's interview sheets

○Kana Yamamoto¹, Haruno Shirasaki^1,2, Saki Hasegawa¹, Ryoko Sakai¹, Manabu Akazawa¹ (1. Meiji Pharmaceutical Univ., 2. Department of Pharmacy,Japanese Red Cross Musashino Hospital)

[31P-am420S] Predictive factors on early discontinuation of liposomal irinotecan in patients with pancreatic cancer

○Minae Shintani¹, Ayaka Iwata¹, Takahiro Ito¹, Hideki Egawa², Serina Hiraoka², Kohei Kamei², Shohei Sano², Kazuo Matsubara^1,2, Masayuki Kitano³, Manabu Kawai³, Manabu Suno¹ (1. School of Pharmaceutical Sciences, Wakayama Medical University, 2. Department of Pharmacy, Wakayama Medical University Hospital, 3. School of Medicine, Wakayama Medical University)

[31P-am421S] Comprehensive Drug-drug Interaction Analysis Based on Cardiotoxicity Reports in a Large Scale Spontaneous Adverse Event Reporting System

○Erika Matsumoto¹, Kenji Onda¹, Daiki Nonami¹, Naho Shojima¹, Ririka Sakamoto¹, Yoshiatsu Ono¹, Kenichi Suzuki¹ (1. Tokyo University of Pharmacy and Life Sciences)

[31P-am422S] An Integrative Analysis on the Effect of Metformin on Peripheral Neuropathy induced by Platinum Anti-cancer Drugs

○Daiki Nonami¹, Kenji Onda¹, Erika Matsumoto¹, Takumi Naito¹, Tomoya Suzuki¹, Kenichi Suzuki¹ (1. Tokyo University of Pharmacy and Life Sciences)

[31P-am423] Effect of anti-MRSA drugs on cancer cell proliferation and its mechanism

○Masahiko Imai¹, Shinya Hasegawa¹, Masahiro Yamasaki¹, Noriko Takahashi^1,2 (1. Hoshi Univ., 2. Research Institute for Production Development)

[31P-am424S] Effects of SGLT2 inhibitors on the growth inhibitory effects of anticancer drugs used for FOLFIRINOX therapy in pancreatic cancer cell line

○Ayane Kimura¹, Genki Sadachi¹, Hiroyuki Tanaka¹, Kotoko Nakano¹, Ayumu Niwai¹, Masayuki Tsujimoto¹, Kohshi Nishiguchi¹ (1. Kyoto Pharm. Univ.,)

[31P-am425S] Skin injury mitigation by cold compress in Vinorelbine-extravasation “analysis of cell cycle and microtubule inhibition”

○Kaya Tamura¹, Ai Shimazaki¹, Masaki Takaishi¹, Akio Kobayashi¹ (1. Pharm.Sci.,IUHW,)

[31P-am426S] Enhancement of toxic effects by additives in skin injury by the Paclitaxel injection or Docetaxel injection

○Ruri Itaya¹, Masaki Takaishi¹, Akio Kobayashi¹ (1. Pharm. Sci., IUHW.)

[31P-am427] Severe thrombocytopenia in breast cancer patient treated with trastuzumab emtansine

○Kaori Nakatani^1,2, Kenji Momo¹, Masaoki Kin², Sadako Akashi³ (1. Sch. Pharm,Showa Univ., 2. Showa Univ. Hosp., 3. Tokyo Women's Med. Univ.)

[31P-am428S] Effects of hypoxic environment on metastatic in PARP inhibitor-resistant human breast cancer cell lines

○Natsuki Yamada¹, Risa Yoshida¹, Hina Tokutake¹, Shugo Hirobayashi¹, Yuna Murayama¹, Masayuki Tsujimoto¹, Kohshi Nishiguchi¹ (1. Kyoto Pharm. Univ.,)

[31P-am429] Therapeutic strategy targeting alterations to cancer energy metabolism by tyrosine kinase inhibition in leukemia cells.

○Takuya Hirao¹, Daiki Ichinose¹, Aoi Sato¹, Natsumi Kaneko¹, Shigeki Aoki², Chihiro Tetsuka^1,3, Yoshinori Kato^1,3, Harumi Yamada^1,3 (1. Sch. Pharm. Sci., Int. Univ. Health and Welfare, 2. Grad. Sch. Pharm. Sci., Chiba Univ., 3. Grad. Sch. Pharm. Sci., Int. Univ. Health and Welfare)

[31P-am430S] Establishment of an allogeneic leukemia model in mice to evaluate the efficacy of kinase inhibitors.

○Mayu Terakawa¹, Takuya Hirao¹, Shiori Kawamata¹, Shigeki Aoki², Chihiro Tetsuka^1,3, Yoshinori Kato^1,3, Harumi Yamada^1,3 (1. Sch. Pharm. Sci., int. Univ.Health and Welfare, 2. Grad. Sch. Pharm. Sci.,Chiba Univ., 3. Grad.Sch. Pharm. Sci., int. Univ.Health and Welfare)

[31P-am431S] Investigating the Relationship between Safety of Immune Checkpoint Inhibitors in Elderly Cancer Patients and Geriatric Screening Tool

○Daiki Yanagishita¹, Taichi Abe², Tatsuya Sumiya², Kaoru Kigasawa¹, Shoko Satake¹, Tomoko Suzuki³, Toru Sato¹, Emiko Iguchi² (1. Yokohama University of Pharmacy, 2. Pharmaceutical Department, Yokohama City Minato Red Cross, 3. International University of Health and Welfare)

[31P-am432] Flavacitropone A, homoacridone-flavanone dimer, induces autophagic cell death via p53 pathways in human pre-B cell leukemia cells.

○Takuya Matsui^1,2, Chihiro Ito² (1. Department of Physiology, School of Medicine, Aichi Medical University, 2. Faculty of Pharmacy, Meijo Univeristy)

[31P-am433] Analysis of rituximab blood concentration in patients with B-cell non-Hodgkin lymphoma.

○Shoko Sato¹, Noriko Fukuhara², Kyoko Inokura², Masahito Himuro³, Keiko Aizawa⁴, Satoshi Ito⁴, Yasuyuki Agatsuma¹, Kenichi Ishizawa⁵ (1. Tohoku medical and pharmaceutical university, 2. Tohoku University Hospital, 3. Himuro clinic, 4. Yamagata University Hospital, 5. Tohoku Fukushi University)

[31P-am434] Oxidative stress mediated acquisition of drug resistance in dacarbazine resistant mouse melanoma cells

○Chinami Ikushima¹, Noriko Yoshikawa¹, Miya Nakamura¹, Satomi Kagota¹, Kazumasa Shinozuka¹, Kazuki Nakamura¹ (1. Dept. Pharm., Mukogawa Women's Univ.)

[31P-am435] Effect of platelets on the malignancy of mouse melanoma cells

○Noriko Yoshikawa¹, Chinami Ikushima¹, Nanako Tanaka¹, Miya Nakamura¹, Satomi Kagota¹, Kazumasa Shinozuka¹, Kazuki Nakamura¹ (1. Dept. Pharm., Mukogawa Women's Univ)

[31P-am436S] Protected effect of SGLT2 inhibitor against elevated urine protein with bevacizumab

○Mayu Ishida¹, Shota Torii², Aya Torii¹, Takashi Sakakibara², Norio Takimoto², Takahiro Hayashi¹ (1. College of Pharmacy, Kinjo Gakuin University, 2. Department of Pharmacy, Kariya Toyota General Hospital)

[31P-am437S] Exploration of genetic polymorphisms in SLC46A3 that affect the efficacy of trastuzumab emtansine

○Naoki Saito¹, Ryuto Tomabechi², Yuka Kawakita¹, Keisuke Kiyomiya¹, Hisanao Kishimoto¹, Kei Higuchi¹, Katsuhisa Inoue¹ (1. Grad. Sch. Pharm. Sci., Tokyo Univ. Pharm., 2. Grad. Sch. Pharm. Sci., Kitasato Univ.)

[31P-am438S] Evaluation of the NUDT15 enzymatic activity in human blood samples for dosage design of thiopurine drugs

○Hitomi Okamoto¹, Yoichi Tanaka², Kazuki Niioka³, Yoshio Shibagaki^1,3, Satoshi Kuronuma⁴, Satoko Umeda⁵, Osamu Takeuchi⁴, Taku Kobayashi⁵, Mitsuru Okuwaki^1,3 (1. Grad. Sch. Pharm., Kitasato Univ., 2. Nat Inst. Health Sci., 3. Sch. Pharm., Kitasato Univ., 4. Dep. Res., Kitasato Univ. Kitasato Inst. Hospital, 5. IBD center, Kitasato Univ. Kitasato Inst. Hospital)

[31P-am439S] Predictivity of the nonclinical toxicity studies on adverse events in the clinical trials of the new drugs for the anti-diabetes drugs

○Mizuki Arima¹, Masaru Saito¹, Masaki Takaishi¹, Akio Kobayashi¹ (1. Pharm. Sci., IUHW.)

[31P-am440S] Predictivity of the nonclinical toxicity studies on adverse events in the clinical trials of the new drugs for the autoimmune diseases

○Masaru Saito¹, Mizuki Arima¹, Masaki Takaishi¹, Akio Kobayashi¹ (1. Pharm. Sci., IUHW.)

[31P-am441] The effect of cross-checking medications with outpatient during medication instruction on the reduction of dispensing-related incidents.

○Misuzu Ota^1,2, Hiroshi Ishimoto¹, Motoki Arakawa³, Shinji Hidaka³, Yuri Takahashi Ikeuchi², Takashi Tomita^1,4, Miki Shimizu¹ (1. Sanno Hospital, 2. Hoshi Univ., 3. Nihon Univ., 4. IUHW Mita hospital)

[31P-am442] Characteristics of duplicate prescriptions of drugs with the same indication based on analysis of pharmacy near-miss cases

○Daiki Mori¹, Takashi Koike¹, Miyoshi Kawakami¹, Miki Saito¹, Kenichi Negishi¹ (1. Sch.Pharm.,Kitasato Univ.)

[31P-am443] Pharmacists' influence on medical safety

○Satoshi Tanaka¹, Yuta Agatsuma¹ (1. South Miyagi Medical Center)

[31P-am444] The Impact of Ink Color for Single Dose Labeling on Medication Errors

○Ryota Shima¹, Tomohisa Hayakawa¹, Yuka Ikebuchi², Jun Hakamata¹, Taketo Ezaki¹, Hiroshi Muramatsu¹, Hisakazu Ohtani^1,3 (1. Keio University Hospital Pharmacy Department, 2. Keio University Hospital Medical Safety Management Department, 3. Keio University School of Medicine)

[31P-am445S] Relationship between breakfast time habits and glycemic control after starting clinic visit in patients with type 2 diabetes melitus

○Natsuho Nemoto¹, Akifumi Kushiyama¹, Ayaka Sugiura¹, Haruka Ota¹, Momoka Kojima¹, Iori Yamazaki¹, Takako Kikuchi², Ryoko Sakai¹, Manabu Akazawa¹ (1. Meiji Pharm. Univ., 2. Inst. Med. Sci., Asahi Life Found.)

[31P-am446S] Exploratory study on the relation between condition items of the simplified diabetic neuropathy diagnostic criteria and retinopathy in type2 diabetic patients

○Ayaka Sugiura¹, Natsuho Nemoto¹, Haruka Ota¹, Momoka Kojima¹, Iori Ymazaki¹, Akifumi Kushiyama¹, Takako Kikuchi², Ryoko Sakai¹, Manabu Akazawa¹ (1. Meiji Pharm.Univ., 2. Inst.Med.Sci)

[31P-am447S] Association of past history of obesity with type 2 diabetes complications

○Haruka Ota¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Momoka Kojima¹, Iori Yamazaki¹, Ayaka Sugiura¹, Natsuho Nemoto¹, Manabu Akazawa¹, Ryoko Sakai¹, Takako Kikuchi², Akifumi Kushiyama¹ (1. Meiji Pharm. Univ, 2. Inst. Med. Sci., Asahi Life Found.)

[31P-am448S] Association of low-density lipoprotein cholesterol with diabetic retinopathy in patients with type 2 diabetes mellitus

○Momoka Kojima¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Manabu Akazawa¹, Ryoko Sakai¹, Haruka Ota¹, Iori Yamazaki¹, Ayaka Sugiura¹, Natsuho Nemoto¹, Takako Kikuchi², Akifumi Kushiyama¹ (1. Meiji Pharm. Univ., 2. Inst. Med. Sci., Asahi Life Found.)

[31P-am449S] Association of hyperuricemia with development and progression of retinopathy in patients with type 2 diabetes mellitus

○iori yamazaki¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Haruka Ota¹, Momoka Kojima¹, Ayaka Sugiura¹, Natsuho Nemoto¹, Manabu Akazawa¹, ryoko Sakai¹, Takako Kikuchi², Akifumi Kushiyama¹ (1. Meiji Pharm. Univ., 2. Inst. Med. Sci., Asahi Life Found.)

[31P-am450S] Relationship between age of diabetes onset and age at menopause in women with type 2 diabetes

○Chihiro Igarashi¹, Msahiro Tkahasi¹, Daisuke Yamamuro¹, Nako Koyama¹, Yuina Goto¹, Chisa Yamaguchi¹, Takako Kikuchi², Akihumi Kusiyama¹, Manabu Akazawa¹, Ryoko Sakai¹ (1. Meiji Pharm.Univ., 2. Inst.Med.Sci.,Asahi Life Found.)

[31P-am451S] Changes in liver fibrosis Indices after first visit in patients with type 2 diabetes mellitus

○Nako Koyama¹, Akifumi Kushiyama¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Chihiro Igarashi¹, Yuina Goto¹, Chisa Yamaguchi¹, Takako Kikuchi², Manabu Akasawa^2,1, Ryoko Sakai¹ (1. Meiji Pharm.Univ., 2. Inst.Med.Sci.,Asahi Life Found.)

[31P-am452S] Association between oral hypoglycemic agents and endoscopic cancer prone lesions in patients with type 2 diabetes mellitus

○Chisa Yamaguchi¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Chihiro Igarashi¹, Nako Koyama¹, Yuina Goto¹, Takako Kikuchi², Akihumi Kushiyama¹, Manabu Akazawa¹, Ryoko Sakai¹ (1. Meiji Pharm.Univ, 2. Inst.Med.Sci.,Asahi Life Found)

[31P-am453S] Emotional/cognitive disorders caused by human papillomavirus vaccine: an analysis using the Japanese Adverse Drug Event Report (JADER) database

○Ami Endo¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Akifumi Kushiyama¹ (1. Meiji Pharm. Univ.)

[31P-am454S] Development of a UPLC-MS Method for the Quantification of Suvorexant in Human Plasma

○Sayo Nakamura¹, Masahiro Takahashi¹, Daisuke Yamamuro¹, Akifumi Kushiyama¹ (1. Meiji Pharm. Univ.)

[31P-am455S] Study on the electrolyzed deoxidized and ionized water (18):Efficacy of S-100 on the suppression of whitening phenomenon during eyelash extensions.

○Moeka Nagashima¹, Ken-ichi Shimokawa¹, Yuko Wada¹, Keisuke Okajima², Yoshinao Okajima², Masahiro Okajima², Fumiyoshi Ishii¹ (1. Meiji Pharm. Univ., 2. A.I. System Products)

[31P-am456] Study on the electrolyzed deoxidized and ionized water (19): Efficacy of S-100 on damaged hair

○Koichi Yoshimi¹, Saki Takamura², Yuko Wada², Ken-ichi Shimokawa², Keisuke Okajima^2,3, Yoshinao Okajima^2,3, Masahiro Okajima^2,3, Fumiyoshi Ishii² (1. coreboxx, 2. Meiji Pharm. Univ., 3. A. I. System Products Corp.)

[31P-am457] Study on the electrolyzed deoxidized and ionized water(20) Physicochemical properties of surfactant-free emulsions using S-100 with various oils and thickening agents.

○Natsuki Ichimura¹, Mimori Kawasaki¹, Yui Saito¹, Yuko Wada¹, Ken-ichi Shimokawa¹, Keisuke Okajima^2,1, Yoshinao Okajima^2,1, Masahiro Okajima^2,1, Fumiyoshi Ishii¹ (1. Meiji Pharm. Univ., 2. A. I. System Products Corp.)

[31P-am458] Study on the electrolyzed deoxidized and ionized water (21): Inhalation toxicity evaluation by single administration of S-100

○Yoshinao Okajima^1,2, Yuko Wada¹, Ken-ichi Shimokawa¹, Keisuke Okajima^1,2, Masahiro Okajima^1,2, Fumiyoshi Ishii¹ (1. Meiji Pharm. Univ., 2. A. I. System Products Corp.)

[31P-am459] Evaluation of pharmaceutical properties between brand and generic products: membrane permeation rate of tulobuterol tapes

○yuko wada¹, Misa Fujii¹, Fumiyoshi Ishii¹, Ken-ichi Shimokawa¹ (1. Meiji Pharm Univ)

[31P-am460] Health support effect of health checks and health consultation by pharmacist (19): Measurement of foot pressure and guidance on improving posture and walking style

○Chisato Watanabe¹, Satoko Ennyu¹, Kayo Yotsukura¹, Yuko Wada¹, Ken-ichi Shimokawa¹, Fumiyoshi Ishii¹ (1. Meiji Pharmaceutical University)

Session information

[31P-am] Clinical Pharmacy

Authentication